echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Green leaf pharmaceutical: layout global development strategy and actively integrate into the tide of innovation era

    Green leaf pharmaceutical: layout global development strategy and actively integrate into the tide of innovation era

    • Last Update: 2018-11-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [China Pharmaceutical network enterprise news] in order to thoroughly implement the spirit of the 19th National Congress of the Communist Party of China, summarize and display the changes and achievements of Yantai high tech Zone in economic, social and ecological civilization construction over the past 40 years of reform and opening up In the afternoon of November 13, "Yantai high tech Zone celebrates the 40th anniversary of reform and opening up" entered LVYE Pharmaceutical Group Co., Ltd to learn about its adherence to innovation driven and international development LVYE Pharmaceutical Group is subordinate to LVYE life science group It is an international pharmaceutical company dedicated to the research, development, production and sales of innovative drugs The company was founded in 1994 and listed on the main board of Hong Kong in 2014 Global R & D: strengthen the advantages of the four innovation technology platforms, deeply layout the new technology field green leaf pharmaceutical since its inception, unswervingly focus on the R & D and production of innovative drugs, and become one of the Chinese pharmaceutical companies that conducted clinical trials in the international market as early as possible At present, LVYE pharmaceutical has established R & D centers in Europe, the United States and China to integrate global R & D resources and accelerate the research and development of innovative drugs At present, there are more than 30 domestic products under research and more than 10 overseas products under research "Advanced drug delivery technology" is the advantageous research and development field of LVYE pharmaceutical for many years At present, the microsphere, liposome, transdermal drug delivery and other new preparation technologies of green leaf pharmaceutical have reached the international advanced level Among them, the tumor innovative drug Lipitor, which is independently developed, is a global listed paclitaxel liposome preparation, and is also currently ranked in the market share of paclitaxel drugs in China In addition, the company's product line under research will also usher in the harvest period Risperidone sustained-release microspheres (ly03004) for the treatment of schizophrenia and bi-directional affective disorder have entered the post stage of NDA application preparation Rotigotine sustained-release microspheres (ly03003) for the treatment of Parkinson's disease and anshufaxin sustained-release tablets (ly03005) for the treatment of depression have also entered phase III clinical Green leaf pharmaceutical is also actively distributing and developing innovative compounds and antibodies, cells, gene therapy and intelligent preparations Global manufacturing: promote industrialization and supply chain innovation by benchmarking international quality management system, green leaf pharmaceutical's R & D and production work closely together from the initiation of R & D projects, providing strong guarantee for the transformation of new drugs from laboratory R & D success to commercial production Today, LVYE pharmaceutical's production base in Germany is one of the largest independent transdermal system manufacturers in Europe, with a highly complex process and high technical barriers to transdermal preparation manufacturing workshop The company's microsphere reaction kettle and key equipment of preparation process are all self-developed, which is also one of the world's advanced microsphere preparation production lines, overcoming the problem of microsphere preparation industrialization The green leaf international pharmaceutical science and Technology Industrial Park visited by the reporter started construction in 2009, with a total planning area of 389 mu, a construction area of 283000 square meters and a planned investment of 6 billion yuan Phase I project has been put into use, including injection workshop, quality inspection building, pilot plant, microsphere workshop, antibody workshop and other infrastructure At present, the second phase of the project has also been started, and the third phase of the project will be built according to the group's product line planning The industrial park has established a GMP quality management and control system that is in line with the international standards From product design to plant construction, the whole park is implemented in accordance with international standards, and the product quality is highly controllable On the basis of the existing seven production bases in the world, LVYE pharmaceutical will further make industrial layout for overseas markets, and strive to graft the relatively mature industrial chains of various regions into the world's advanced supply chain, and further build a global supply chain network from the purchase of raw and auxiliary materials at the front end to the supply of terminal patients Global market: green leaf pharmaceutical has more than 30 products, covering more than 80 countries and regions, including China, the United States, the European Union, Japan and other major pharmaceutical markets, as well as high growth international emerging markets Its core products focus on anti-tumor, central nervous system, cardiovascular system, digestion and metabolism, and have a position in their respective market segments At the end of 2016, green leaf pharmaceutical has constructed a rich product line and treatment scheme combination in the global market of central nervous field by purchasing the transdermal preparation business of European company acino, and has created a global business operation mode in the coordination of domestic and foreign R & D, manufacturing and market Since this year, LVYE pharmaceutical has continuously deepened its strategic layout in the global market and its business operation capacity in major pharmaceutical markets and emerging markets through the acquisition of business in 51 countries and regions including AstraZeneca and SRK sustained-release tablets in China, as well as the acquisition of global business of contraceptive transdermal patch product apleek from Bayer The reporter learned that in 2017, LVYE pharmaceutical achieved a sales revenue of 3.82 billion yuan After years of intensive development, LVYE pharmaceutical has found a unique international road, its independent innovation ability and international market competitiveness have been significantly improved, and it has also made continuous contributions to promoting the overall innovation of the pharmaceutical industry Former title: LVYE pharmaceutical: layout global development strategy and actively integrate into the tide of innovation era reporter: Xu Jiawei
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.